Christoph Wandel

2.3k total citations
41 papers, 1.6k citations indexed

About

Christoph Wandel is a scholar working on Molecular Biology, Pediatrics, Perinatology and Child Health and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Christoph Wandel has authored 41 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Pediatrics, Perinatology and Child Health and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Christoph Wandel's work include Muscle Physiology and Disorders (7 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Pharmacological Effects and Toxicity Studies (7 papers). Christoph Wandel is often cited by papers focused on Muscle Physiology and Disorders (7 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Pharmacological Effects and Toxicity Studies (7 papers). Christoph Wandel collaborates with scholars based in United States, Switzerland and United Kingdom. Christoph Wandel's co-authors include Alastair J.J. Wood, Margaret Wood, Richard Kim, Richard B. Kim, G. Wilkinson, Shama Kajiji, G R Wilkinson, Peter J. Dempsey, Frank J. Belas and Martin F. Fromm and has published in prestigious journals such as Neurology, Annals of Neurology and Scientific Reports.

In The Last Decade

Christoph Wandel

41 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christoph Wandel United States	16	734	590	531	280	159	41	1.6k
Janet K. Coller Australia	28	464 0.6×	632 1.1×	426 0.8×	505 1.8×	140 0.9×	78	2.4k
Séverine Crettol Switzerland	18	286 0.4×	586 1.0×	454 0.9×	289 1.0×	253 1.6×	40	1.5k
Koujirou Yamamoto Japan	22	403 0.5×	493 0.8×	165 0.3×	267 1.0×	83 0.5×	102	1.4k
Ingrid Mai Germany	23	532 0.7×	416 0.7×	1.1k 2.0×	228 0.8×	592 3.7×	38	2.4k
Leah M. Hesse United States	17	304 0.4×	537 0.9×	234 0.4×	242 0.9×	104 0.7×	21	1.2k
Dolores Ochoa Spain	25	251 0.3×	548 0.9×	273 0.5×	207 0.7×	301 1.9×	98	1.6k
Mike Ufer Switzerland	25	331 0.5×	381 0.6×	399 0.8×	273 1.0×	172 1.1×	67	1.9k
Edward J. Randinitis United States	18	265 0.4×	232 0.4×	371 0.7×	231 0.8×	246 1.5×	43	1.3k
Samuel M. Poloyac United States	36	245 0.3×	393 0.7×	284 0.5×	940 3.4×	97 0.6×	120	3.4k
Ryan Z. Turncliff United States	18	361 0.5×	217 0.4×	232 0.4×	161 0.6×	191 1.2×	24	1.1k

Countries citing papers authored by Christoph Wandel

Since Specialization

Citations

This map shows the geographic impact of Christoph Wandel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Wandel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Wandel more than expected).

Fields of papers citing papers by Christoph Wandel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Wandel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Wandel. The network helps show where Christoph Wandel may publish in the future.

Co-authorship network of co-authors of Christoph Wandel

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Wandel. A scholar is included among the top collaborators of Christoph Wandel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Wandel. Christoph Wandel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mendell, Jerry R., Crystal M. Proud, Craig M. Zaidman, et al.. (2024). Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy. Pediatric Neurology. 153. 11–18. 14 indexed citations

Zaidman, Craig M., Crystal M. Proud, Craig M. McDonald, et al.. (2023). Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR). Annals of Neurology. 94(5). 955–968. 47 indexed citations

Hipp, Joerg F., Frédéric Knoflach, Robert A. Comley, et al.. (2021). Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. Scientific Reports. 11(1). 7700–7700. 24 indexed citations

Bentley, Darren, et al.. (2020). PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration. Journal of Pharmacokinetics and Pharmacodynamics. 47(5). 447–459. 1 indexed citations

Derks, Michael, et al.. (2020). Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. Advances in Therapy. 37(11). 4720–4729. 4 indexed citations

Hollander, Eric, Suma Jacob, Roger J. Jou, et al.. (2020). A PHASE 2 RANDOMIZED CONTROLLED TRIAL OF BALOVAPTAN IN PEDIATRIC PARTICIPANTS WITH AUTISM SPECTRUM DISORDER. Journal of the American Academy of Child & Adolescent Psychiatry. 59(10). S262–S263. 6 indexed citations

Bolognani, Federico, Marta del Valle Rubido, Lisa Squassante, et al.. (2019). A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine. 11(491). 75 indexed citations

Abt, Markus, et al.. (2019). A Framework Proposal to Follow‐Up on Preclinical Convulsive Signals of a New Molecular Entity in First‐in‐Human Studies Using Electroencephalographic Monitoring. Clinical Pharmacology & Therapeutics. 106(5). 968–980. 2 indexed citations

Kletzl, Heidemarie, Andreas Guenther, Jan Frystyk, et al.. (2017). First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I. Growth Hormone & IGF Research. 33. 9–16. 5 indexed citations

10.

Alexander, M, et al.. (2015). Morbidity and medication in a large population of individuals with Down syndrome compared to the general population. Developmental Medicine & Child Neurology. 58(3). 246–254. 91 indexed citations

11.

Bolognani, Federico, Lisa Squassante, Xavier Liogier D’ardhuy, et al.. (2015). RG1662, a Selective GABAA α5 Receptor Negative Allosteric Modulator, Increases Gamma Power in Young Adults with Down Syndrome. (P6.273). Neurology. 84(14_supplement). 5 indexed citations

12.

Staß, Heino, et al.. (2001). Effect of Calcium Supplements on the Oral Bioavailability of Moxifloxacin in Healthy Male Volunteers. Clinical Pharmacokinetics. 40(Supplement 1). 27–32. 14 indexed citations

13.

Voith, Barbara, et al.. (2000). Safety, tolerability, and pharmacokinetics following multiple oral doses of faropenem daloxate and impact on fecal and oral flora. 40. 15. 3 indexed citations

14.

Wandel, Christoph. (2000). CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clinical Pharmacology & Therapeutics. 68(1). 82–91. 207 indexed citations

15.

Stein, Christoph, et al.. (1999). Cyclosporine pharmacokinetics and pharmacodynamics in African-Americans (AA) and Caucasians (C). Clinical Pharmacology & Therapeutics. 65(2). 160–160. 2 indexed citations

16.

Wandel, Christoph, R. Böcker, H. Böhrer, et al.. (1998). Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally.. PubMed. 26(2). 110–4. 34 indexed citations

17.

Wandel, Christoph, et al.. (1997). The Relationship Between Cytochrome P4502E1 Activity and Plasma Fluoride Levels After Sevoflurane Anesthesia in Humans. Anesthesia & Analgesia. 85(4). 924–930. 13 indexed citations

18.

Wandel, Christoph, et al.. (1995). Lignocaine metabolite formation: an indicator for liver dysfunction and predictor of survival in surgical intensive care patients. Anaesthesia. 50(10). 850–854. 20 indexed citations

19.

Wandel, Christoph, et al.. (1994). Midazolam is metabolized by at least three different cytochrome P450 enzymes. British Journal of Anaesthesia. 73(5). 658–661. 123 indexed citations

20.

Wandel, Christoph, H. Böhrer, & R. Böcker. (1993). Bedeutung der Cytochrom P-450-Superfamilie im Metabolismus anästhesierelevanter Pharmaka. AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie. 28(8). 511–516. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact